# Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

> **NCT03856697** · PHASE3 · UNKNOWN · sponsor: **Hangzhou ACEA Pharmaceutical Research Co., Ltd.** · enrollment: 406 (estimated)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Abivertinib Maleate Capsules
- **DRUG:** Placebo Gefitinib Tablets
- **DRUG:** Gefitinib Tablets
- **DRUG:** Placebo Abivertinib Maleate Capsules

## Key facts

- **NCT ID:** NCT03856697
- **Lead sponsor:** Hangzhou ACEA Pharmaceutical Research Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03
- **Primary completion:** 2022-03
- **Final completion:** 2024-03
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03856697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03856697, "Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03856697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*